This includes not only those tumors in which ERp57/PDIA3 is putatively expressed on the cell surface membrane (i.e., T-cell leukemia 28 and breast cancer 29), but also in tumors expressing no significant cell surface ERp57/PDIA3. This evidence concerns the gene PDIA3 and breast carcinoma.